CTI BioPharma Settles Investor Testing Info Row For $20M
CTI BioPharma Corp. and its executives will pay $20 million to a proposed class of investors for allegedly withholding information about patient deaths during clinical trials for a myelofibrosis drug, which...To view the full article, register now.
Already a subscriber? Click here to view full article